Schultze Special Purpose Acquisition Corp. (SAMAU), the $150 million SPAC focusing on restructured companies, amended their S-1 this morning by adding the “Crescent Term,” which adjusts the warrant strike in the event of the issuance of additional securities in connection with a business combination closing. This term has been used so far in just Megalith Financial and EdTechx, but the originator was the Crescent Funding SPAC, which never actually made it to IPO.
As a refresher for how the term works, if Schultze issues additional shares of common stock or equity-linked securities for capital raising purposes in connection with their combination and the price of those securities are issued at less than $9.50 per share, then the strike price of the public warrants will be adjusted. to be equal to 115% of either the market value or the newly issued price, whichever is higher.
However, in order for the strike price to be adjusted, the gross proceeds from any additional issuances must be greater than 60% of the SPAC proceeds (plus interest and net of redemptions). AND…the market value of the issued share price needs to be below $9.50 per share.
As an example, if Schultze does a PIPE at business combination, but it’s done at effectively $9.51 or above and the total proceeds of the PIPE are less than $90 million (assuming Trust is $150 million at the time), plus the share price is trading at $9.50 or above, the warrant strike will not adjust.
However, if Schultze does a $100 million PIPE at $9.40, but the share is trading at $9.60. Again, no adjustment, because the share’s market value is above $9.50. But…if the share price is trading at $9.49, then the warrant strike will be adjusted.
One important note though: In Megalith’s “Crescent Term”, the redemption trigger was also adjusted along with the warrant strike and this is not adjusted in Schultze “Crescent Term”. Is this meaningful? Only if Schultze does a PIPE at a price far below $10.00.
A summary of Schultze’s terms have been provided below and given that they just re-filed, a Monday pricing is probably in the cards rather than tonight. However, we’ll be watching to see if that changes.
EarlyBirdCapital and BTIG are joint lead underwriting managers.
Greenberg Traurig, LLP and Graubard Miller are issuer’s counsel and underwriter’s counsel, respectively.
AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...
At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...
Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...
At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...
Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...